Vestavia Hills, AL, United States of America

Yahya El-Kattan

This inventor holds 18 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent, primarily in Pharmaceutical Chemistry. Top assignee: Biocryst Pharmaceuticals, Inc.. Active years: 2004-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yahya El-Kattan. Retrieved from https://idiyas.com/inventor/yahya-el-kattan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 18 (Patent Applications = 4)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 2)

Average Co-Inventor Count = 2.7

ph-index = 8

Forward Citations = 265(Granted Patents)

Location History:

Birmingham, AL (US) (2005)
Hoover, AL (US) (2004 - 2008)
Vestavia Hills, AL (US) (2009 - 2023)

Company Filing History:

18 out of 92

Biocryst Pharmaceuticals, Inc.

patents

Years Active: 2004-2026

Loading Chart...

Areas of Expertise:

Plasma Kallikrein Inhibitors

Crystalline Salts

Hepatitis C Therapies

Therapeutic Furopyrimidines

Thienopyrimidines

Nucleosides

RNA Viral Polymerases

Substituted Pyrrolidine Derivatives

Biaryl Compounds

Serine Protease Inhibitors

Process-Scale Synthesis

Preparation Methods

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12590069 - Crystalline salts of a plasma kallikrein inhibitor (2026-03-31),

2. 12590068 - Crystalline salts of a plasma kallikrein inhibitor (2026-03-31),

3. 12552750 - Crystalline salts of a plasma kallikrein inhibitor (2026-02-17),

4. 12545647 - Crystalline salts of a plasma kallikrein inhibitor (2026-02-10),

5. 12545646 - Crystalline salts of a plasma kallikrein inhibitor (2026-02-10),

6. 12545645 - Crystalline salts of a plasma kallikrein inhibitor (2026-02-10),

7. 12503443 - Process-scale synthesis of a plasma kallikrein inhibitor (2025-12-23),

8. 12344585 - Crystalline salts of a plasma kallikrein inhibitor (2025-07-01),

9. 11618733 - Crystalline salts of a plasma kallikrein inhibitor (2023-04-04),

10. 11117867 - Crystalline salts of a plasma kallikrein inhibitor (2021-09-14),

11. 10662160 - Crystalline salts of a plasma kallikrein inhibitor (2020-05-26),

12. 8163703 - Hepatitis C therapies (2012-04-24),

13. 8133870 - Therapeutic furopyrimidines and thienopyrimidines (2012-03-13),

14. 7514410 - Hepatitis C therapies (2009-04-07),

15. 7388002 - Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases (2008-06-17),

Title: **Yahya El-Kattan: Innovator in Pharmaceutical Sciences**

Introduction

Yahya El-Kattan is a distinguished inventor based in Vestavia Hills, Alabama. With an impressive portfolio of 11 patents, he has made significant contributions to the field of pharmaceutical sciences, particularly in the development of innovative therapies.

Latest Patents

Among his noteworthy achievements, El-Kattan's latest patents include the invention of crystalline salts of a plasma kallikrein inhibitor. This patent outlines the methods of preparing these crystalline salts, along with their related pharmaceutical preparations. Furthermore, it also describes methods of treatment using these innovative salts, showcasing his dedication to advancing medical treatments.

Career Highlights

Currently, El-Kattan is employed at Biocryst Pharmaceuticals, Inc., where he plays a pivotal role in researching and developing novel therapeutic solutions. His work exemplifies a commitment to transforming complex scientific concepts into practical applications that can improve patient outcomes.

Collaborations

Throughout his career, El-Kattan has collaborated with esteemed colleagues, including Yarlagadda Sudhakara Babu and Pooran Chand. These partnerships foster a rich exchange of ideas and expertise, further enhancing the innovative projects they undertake together.

Conclusion

Yahya El-Kattan stands out as a leading inventor in the pharmaceutical industry, with a remarkable track record of patents that address critical medical needs. His ongoing work at Biocryst Pharmaceuticals, alongside talented collaborators, promises to continue impacting the field positively and pave the way for future innovations.

Profile summary based on public USPTO records.